Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.
News stories up to a week old on LSIPR are accessible with a FREE registration.
Feature articles are FREE to access on the day they are published with a FREE registration. After then you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email firstname.lastname@example.org.
For access to the complete website, archive, and to receive print publications, choose 'SUBSCRIBER'. For a free, two-week trial with full access, select ‘FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'FREE' registration.
actavis, oxycontin, purdue pharma, Fitzpatrick, Cella, Harper & Scinto